Biosimilars Market, Europe, Forecast to 2025
Biosimilars Market, Europe, Forecast to 2025
A Growing Number of Incentive Policies to Propel Growth in the Next 5–7 Years, with Oncology as the Fastest Adopter
29-Mar-2017
Europe
Description
Patent expiration and increased use of traditional generic drugs are leading to a shift of focus in the pharmaceutical industry toward investment in specialty drugs and high growth areas such as biosimilars. Expensive biopharmaceuticals are largely used for life-saving disorders such as cancer and diabetes, the incidence of which is increasing with population aging in Europe. Moreover, patent expiry of key product classes and a growing emphasis on cost effectiveness are making governments switch to affordable alternatives. There is thus a tremendous opportunity for biosimilar manufacturers. However, the development of biosimilar drugs is riddled with complexities, from R&D to manufacturing to marketing, and is one of the most expensive propositions in the pharmaceutical industry.
About 30 companies are actively developing biosimilar medicines and are researching on the biosimilar versions of 16 distinct molecules that will lead to greater competition by 2020, with 8 major biologic medicines expected to lose exclusivity by 2020.
The next five years are going to be an interesting period in the biosimilars market as a number of biologic drugs are going to lose their exclusivity. On the one hand, this will significantly reduce costs for patients and health systems, on the other, it will pose challenges for regulators to confirm the similarity of the biosimilar to the original biologic in terms of efficacy and safety. The experience of European healthcare companies has been encouraging in the 10 years since the endorsement of the first biosimilar in the EU.
Pricing and physician awareness and support from the regulatory agencies are expected to be key factors driving success in the biosimilars market. Europe is expected to remain the largest contributor to biosimilars revenue worldwide for the next 5–7 years.
The study analyzes the supply market dynamics and forecasts future revenues for key biosimilars in the European region. It also identifies the six key issues to determine the strategic imperatives for success and growth in this market. Moreover, it includes an in-depth analysis of the biosimilar value chain and the payer and regulatory environment. By assessing the impact of trends, disruptive technologies, and new business models, the study arrives at key visioning scenarios for the biosimilars market in Europe. These will help market participants make strategic decisions, stay ahead of their competitors, and gain a significant share in the market. The study also sheds light on strategic partnerships among companies in the European biosimilars market.
Highlights of the report include:
• Growth Opportunities and Challenges
• Supply Market Dynamics
• Payer and Regulatory Environment Analysis
• Strategic Imperatives for Success and Growth–The Six Tactical Issues
• Visioning Scenarios for the Biosimilars Market
• Business Model Essentials
• A Macro Overview of the Biosimilars Market
Table of Contents
Pharma/Biotech Market—Emerging Trends
Market Snapshot—Biosimilars
Revenue Forecast
Revenue Forecast by Region
Percent Revenue Forecast by Region
Biosimilars Ecosystem—Industry Convergence Map
Ecosystem Partnerships—An Opportunity
Changing Market Scenario—Disruptive Trends
Patent Expiries
Key Regions
Technology Innovation
Global Biosimilars Industry—Six Big Market Themes
Market Overview
Key Challenges in the Biosimilars Market
Market Segmentation by Therapeutic Areas
Trends in the Global Biosimilars Market
Global Biosimilar Patenting Trends
Biosimilars Adoption—Key Determinants
Physician Adoption of Biosimilars—Major Determinants
Drivers and Restraints
Impact Mapping of Drivers and Restraints
Percent Revenue Forecast by Region
Revenue Forecast
Revenue Forecast by Molecule Type
Snapshot—EU Biosimilars Market
Opportunity Heat Map—European Biosimilars Market.
Top-selling Biotech Drugs
Growth Opportunities in Oncology
Trastuzumab Biosimilars Adoption Rate
Trastuzumab Biosimilars Patient Population
Trastuzumab Biosimilars
Bevacizumab Biosimilars
Top-selling Biotech Drugs
Growth Opportunities in Diabetes
Insulin Glargine Biosimilars
Top-selling Biotech drugs
Growth Opportunities in Rheumatoid Arthritis
Etanercept Biosimilars
Infliximab Biosimilars
Adalimumab Biosimilars
Challenge 1—Interchangeability
Challenge 2—Innovation in Biologics and Biobetters
Future of Biosimilars in Europe
Competitive Landscape Analysis
Market Analysis—Europe
Regional Hot Spots—EU5 Perspective
Country Attractiveness
Biosimilar Uptake in Scandinavia—A Case Study
Key Companies to Watch
Merger, Acquisition, and Partnership Assessment
Biosimilars under Review by EMA
Payer Environment
Regulatory Environment
Impact of Policies—An EU5 Perspective
Development Process and Technical Requirements
Business Models to Mitigate Concerns over Cost
Strategic Imperatives for Success and Growth
Strategies for Innovators—Case Studies
Strategies for Foreign Participants in the EU
Visioning Scenarios for the Biosimilars Market
Business Model Essentials
Competitive Keys for Success in the Biosimilars Market
Legal Disclaimer
Global Regulatory Landscape
Impact of Regulations in the Biosimilars Market
Biosimilars are Not Generics—A Comparison of Generics, Biologics, and Biosimilars
Biologics and Biosimilars—Differences in Manufacturing Processes
Development Process and Technical Requirements for Biosimilars
Timeline for the Development of a Biosimilar Medicine
Value Chain Analysis—Development of a Biosimilar
Market Evolution of Biosimilars, 2015
Comparing the Players—Big Pharma (Innovators), Biotech Firms, and Generic Manufactures
List of Biosimilars Approved in Europe
List of Biosimilars under Review by EMA
- 1. Total Biosimilar Market: Key Biologic Patent Losses, Europe, 2004–2021
- 2. Total Biosimilars Market: Key Trends, Global, 2016
- 3. Total Biosimilars Market: Major Patent Expiries: Europe and US, 2000–2030
- 4. Total Biosimilars Market: Key Regions, Global, 2016
- 5. Total Biosimilars Market: Market Trends, Europe, 2016
- 6. Total Biosimilars Market: Key Trends and Highlights, Global, 2016
- 7. Total Biosimilars Market: Biosimilars Adoption, Key Determinants, Global, 2017–2025
- 8. Total Biosimilars Market: Biologic versus Biosimilar, Global, 2015
- 9. Total Biosimilars Market: Key Market Drivers and Restraints, Europe, 2017–2025
- 10. Total Biosimilars Market: Impact Mapping of Drivers and Restraints, Europe, 2017–2025
- 11. Total Biosimilars Market: Biosimilars Snapshot, Europe, 2017–2025
- 12. Total Biosimilars Market: Opportunity Heat Map, Europe, 2017–2025
- 13. Oncology Therapeutic Segment: Top-selling Biotech Drugs, Europe, 2015
- 14. Oncology Therapeutic Segment: Growth Opportunities, Europe, 2016–2025
- 15. Oncology Therapeutic Segment: Trastuzumab Biosimilars Adoption Rate, Europe, 2014–2025
- 16. Oncology Therapeutic Segment: Trastuzumab Patient Population, Europe, 2014 and 2025
- 17. Oncology Therapeutic Segment: Herceptin® Price and Biosimilars Discount, Europe, 2014–2025
- 18. Oncology Therapeutic Segment: Bevacizumab Biosimilars Adoption Rate, Europe, 2014–2025
- 19. Oncology Therapeutic Segment: Bevacizumab Patient Population, Europe, 2014 and 2025
- 20. Oncology Therapeutic Segment: Avastin® Price and Biosimilars Discount, Europe, 2014–2025
- 21. Diabetes Therapeutic Segment: Top Selling Biotech Drugs, Europe, 2015
- 22. Diabetes Therapeutic Segment: Growth Opportunities, Europe, 2016–2025
- 23. Diabetes Therapeutic Segment: Insulin Glargine Biosimilars Adoption Rate, Europe, 2014–2025
- 24. Diabetes Therapeutic Segment: Insulin Glargine Biosimilars Patient Population, Europe, 2014 and 2025
- 25. Diabetes Therapeutic Segment: Lantus Price and Biosimilars Discount, Europe, 2014–2025
- 26. Rheumatoid Arthritis Therapeutic Segment: Top-selling Biotech Drugs, Europe, 2015
- 27. Rheumatoid Arthritis Therapeutic Segment: Growth Opportunities, Europe, 2016–2025
- 28. Rheumatoid Arthritis Therapeutic Segment: Etanercept Biosimilars Adoption Rate, Europe, 2014–2025
- 29. Rheumatoid Arthritis Therapeutic Segment: Etanercept Biosimilar Patient Population, Europe, 2014 and 2025
- 30. Rheumatoid Arthritis Therapeutic Segment: Enbrel® Price and Biosimilars Discount, Europe, 2014–2025
- 31. Rheumatoid Arthritis Therapeutic Segment: Infliximab Biosimilars Adoption Rate, Europe, 2014–2025
- 32. Rheumatoid Arthritis Therapeutic Segment: Infliximab Biosimilars Patient Population, Europe, 2014 and 2025
- 33. Rheumatoid Arthritis Therapeutic Segment: Remicade® Price and Biosimilars Discount, Europe, 2014–2025
- 34. Rheumatoid Arthritis Therapeutic Segment: Adalimumab Biosimilars Adoption Rate, Europe, 2014–2025
- 35. Rheumatoid Arthritis Therapeutic Segment: Adalimumab Biosimilars Patient Population, Europe, 2014 and 2025
- 36. Total Biosimilars Market: Key M&A Assessment, Europe, 2015–16
- 37. Total Biosimilars Market: Key M&A Assessment, Europe, 2015–16
- 38. Total Biosimilars Market: Key Biosimilars under Review, Europe, 2015–16
- 39. Total Biosimilars Market: Regulatory Approval Pathway in Europe, 2016
- 40. Total Biosimilars Market: Impact of Country-level Policies, Europe, 2016
- 41. Total Biosimilars Market: Strategies for Foreign Participants, Europe, 2016
- 42. Total Biosimilars Market: Assessing the Future Impact of Trends, Disruptive Technologies, and New Business Models, Europe, 2016–2025
- 43. Total Biosimilars Market: Comparison of Generics, Biologics, and Biosimilars, Europe, 2016
- 44. Total Biosimilars Market: Key Trends and Highlights, Global, 2015–2016
- 45. Total Biosimilars Market: Differences in the Manufacturing Processes of Biologics and Biosimilars, Global, 2015–2016
- 46. Total Biosimilars Market: Data Requirements for Biosimilar Development, Global, 2016
- 47. Total European Biosimilars Market: Timeline of Key Events, Global, 2015
- 48. Total Biosimilars Market: A Comparison of Market Players, Europe, 2016
- 49. Total Biosimilars Market: List of Biosimilars Approved, Europe, 2016
- 50. Total Biosimilars Market: List of Biosimilars under Review by EMA, Europe, 2016
- 1. Total Biosimilar Market: Percent Revenue Forecast by Region, Global, 2016 and 2025
- 2. Total Biosimilars Market: Revenue Forecast, Global, 2015–2025
- 3. Total Biosimilars Market: Revenue Forecast by Region, Global, 2015–2025
- 4. Total Biosimilars Market: Percent Revenue Forecast by Region, Global, 2015–2025
- 5. Total Biosimilars Market: Impact Mapping of Drivers and Restraints, Europe, 2017–2025
- 6. Total Biosimilars Market: Percent Revenue Forecast by Region, Global, 2015–2025
- 7. Total Biosimilars Market: Revenue Forecast, Europe, 2015–2025
- 8. Total Biosimilars Market: Revenue Forecast by Molecule Type, Europe, 2015–2025
- 9. Oncology Therapeutic Segment: Trastuzumab Patient Population Forecast, Europe, 2015–2025
- 10. Oncology Therapeutic Segment: Trastuzumab Revenue Forecast, Europe, 2015–2025
- 11. Oncology Therapeutic Segment: Bevacizumab Biosimilars Patient Population Forecast, Europe, 2015–2025
- 12. Oncology Therapeutic Segment: Bevacizumab Biosimilars Revenue Forecast, Europe, 2015–2025
- 13. Diabetes Therapeutic Segment: Insulin Glargine Biosimilars Patient Population Forecast, Europe, 2015–2025
- 14. Diabetes Therapeutic Segment: Insulin Glargine Biosimilars Revenue Forecast, Europe, 2015–2025
- 15. Rheumatoid Arthritis Therapeutic Segment: Etanercept Biosimilars Patient Population Forecast, Europe, 2015–2025
- 16. Rheumatoid Arthritis Therapeutic Segment: Etanercept Revenue Forecast, Europe, 2015–2025
- 17. Rheumatoid Arthritis Therapeutic Segment: Infliximab Biosimilars Patient Population Forecast, Europe, 2015–2025
- 18. Rheumatoid Arthritis Therapeutic Segment: Infliximab Revenue Forecast, Europe, 2015–2025
- 19. Rheumatoid Arthritis Therapeutic Segment: Adalimumab Biosimilars Patient Population Forecast, Europe, 2015–2025
- 20. Rheumatoid Arthritis Therapeutic Segment: Adalimumab Revenue Forecast, Europe, 2015–2025
- 21. Total Biosimilars Market: Percent of Sales, Europe, 2015
- 22. Total Biosimilars Market: Regional Growth Rates, Global, 2015
- 23. Total Biosimilars Market: Adoption of Biosimilar Infliximab as a % of the Total Infliximab Market, Scandinavia, 2016
- 24. Total Biosimilars Market: Timeline for the Development of a Biosimilar Medicine, Global, 2015–2016
Popular Topics
No Index | No |
---|---|
Podcast | No |
Table of Contents | | Executive Dashboard~ || Pharma/Biotech Market—Emerging Trends~ || Market Snapshot—Biosimilars~ || Revenue Forecast~ || Revenue Forecast by Region~ || Percent Revenue Forecast by Region~ || Biosimilars Ecosystem—Industry Convergence Map~ || Ecosystem Partnerships—An Opportunity~ || Changing Market Scenario—Disruptive Trends~ || Patent Expiries~ || Key Regions~ || Technology Innovation~ || Global Biosimilars Industry—Six Big Market Themes~ | Growth Environment~ || Market Overview~ || Key Challenges in the Biosimilars Market~ || Market Segmentation by Therapeutic Areas~ || Trends in the Global Biosimilars Market~ || Global Biosimilar Patenting Trends~ || Biosimilars Adoption—Key Determinants~ || Physician Adoption of Biosimilars—Major Determinants~ | Drivers and Restraints—Total European Biosimilars Market~ || Drivers and Restraints~ || Impact Mapping of Drivers and Restraints~ | Growth Opportunity and Market Forecast—Total European Biosimilars Market~ || Percent Revenue Forecast by Region~ || Revenue Forecast~ || Revenue Forecast by Molecule Type~ || Snapshot—EU Biosimilars Market~ || Opportunity Heat Map—European Biosimilars Market.~ | Growth Opportunity and Market Forecast of Key Biosimilars—Oncology~ || Top-selling Biotech Drugs~ || Growth Opportunities in Oncology~ || Trastuzumab Biosimilars Adoption Rate~ || Trastuzumab Biosimilars Patient Population~ || Trastuzumab Biosimilars~ ||| Patient Population Forecast~ ||| Pricing and Discounts~ ||| Revenue Forecast~ || Bevacizumab Biosimilars~ ||| Adoption Rate~ ||| Patient Population~ ||| Patient Population Forecast~ ||| Pricing and Discounts~ ||| Revenue Forecast~ | Growth Opportunity and Market Forecast of Key Biosimilars—Diabetes~ || Top-selling Biotech Drugs~ || Growth Opportunities in Diabetes~ || Insulin Glargine Biosimilars~ ||| Adoption Rate~ ||| Patient Population~ ||| Patient Population Forecast~ ||| Pricing and Discounts~ ||| Revenue Forecast~ | Growth Opportunity and Market Forecast of Key Biosimilars—Rheumatoid Arthritis~ || Top-selling Biotech drugs~ || Growth Opportunities in Rheumatoid Arthritis~ || Etanercept Biosimilars~ ||| Adoption Rate~ ||| Patient Population~ ||| Patient Population Forecast~ ||| Pricing and Discounts~ ||| Revenue Forecast~ || Infliximab Biosimilars~ ||| Adoption Rate~ ||| Patient Population~ ||| Patient Population Forecast~ ||| Pricing and Discounts~ ||| Revenue Forecast~ || Adalimumab Biosimilars~ ||| Adoption Rate~ ||| Patient Population~ ||| Patient Population Forecast~ ||| Pricing and Discounts~ ||| Revenue Forecast~ | Market Challenges—Biosimilars~ || Challenge 1—Interchangeability~ || Challenge 2—Innovation in Biologics and Biobetters~ | Supply Market Dynamics—Europe~ || Future of Biosimilars in Europe ~ || Competitive Landscape Analysis~ || Market Analysis—Europe~ || Regional Hot Spots—EU5 Perspective~ || Country Attractiveness~ || Biosimilar Uptake in Scandinavia—A Case Study~ || Key Companies to Watch~ || Merger, Acquisition, and Partnership Assessment~ || Biosimilars under Review by EMA~ | Strategic Imperatives and Critical Success Factors for Europe~ || Payer Environment~ || Regulatory Environment~ || Impact of Policies—An EU5 Perspective~ || Development Process and Technical Requirements~ || Business Models to Mitigate Concerns over Cost~ || Strategic Imperatives for Success and Growth~ || Strategies for Innovators—Case Studies~ || Strategies for Foreign Participants in the EU~ | Conclusion~ || Visioning Scenarios for the Biosimilars Market~ || Business Model Essentials~ || Competitive Keys for Success in the Biosimilars Market~ || Legal Disclaimer~ | Appendix~ || Global Regulatory Landscape~ || Impact of Regulations in the Biosimilars Market~ | Introduction to Biosimilars~ || Biosimilars are Not Generics—A Comparison of Generics, Biologics, and Biosimilars~ || Biologics and Biosimilars—Differences in Manufacturing Processes~ || Development Process and Technical Requirements for Biosimilars~ || Timeline for the Development of a Biosimilar Medicine~ || Value Chain Analysis—Development of a Biosimilar~ || Market Evolution of Biosimilars, 2015~ || Comparing the Players—Big Pharma (Innovators), Biotech Firms, and Generic Manufactures~ || List of Biosimilars Approved in Europe~ || List of Biosimilars under Review by EMA~ |
List of Charts and Figures | 1. Total Biosimilar Market: Key Biologic Patent Losses, Europe, 2004–2021~ 2. Total Biosimilars Market: Key Trends, Global, 2016~ 3. Total Biosimilars Market: Major Patent Expiries: Europe and US, 2000–2030~ 4. Total Biosimilars Market: Key Regions, Global, 2016~ 5. Total Biosimilars Market: Market Trends, Europe, 2016~ 6. Total Biosimilars Market: Key Trends and Highlights, Global, 2016~ 7. Total Biosimilars Market: Biosimilars Adoption, Key Determinants, Global, 2017–2025~ 8. Total Biosimilars Market: Biologic versus Biosimilar, Global, 2015~ 9. Total Biosimilars Market: Key Market Drivers and Restraints, Europe, 2017–2025~ 10. Total Biosimilars Market: Impact Mapping of Drivers and Restraints, Europe, 2017–2025~ 11. Total Biosimilars Market: Biosimilars Snapshot, Europe, 2017–2025~ 12. Total Biosimilars Market: Opportunity Heat Map, Europe, 2017–2025~ 13. Oncology Therapeutic Segment: Top-selling Biotech Drugs, Europe, 2015 ~ 14. Oncology Therapeutic Segment: Growth Opportunities, Europe, 2016–2025~ 15. Oncology Therapeutic Segment: Trastuzumab Biosimilars Adoption Rate, Europe, 2014–2025~ 16. Oncology Therapeutic Segment: Trastuzumab Patient Population, Europe, 2014 and 2025~ 17. Oncology Therapeutic Segment: Herceptin® Price and Biosimilars Discount, Europe, 2014–2025~ 18. Oncology Therapeutic Segment: Bevacizumab Biosimilars Adoption Rate, Europe, 2014–2025~ 19. Oncology Therapeutic Segment: Bevacizumab Patient Population, Europe, 2014 and 2025~ 20. Oncology Therapeutic Segment: Avastin® Price and Biosimilars Discount, Europe, 2014–2025~ 21. Diabetes Therapeutic Segment: Top Selling Biotech Drugs, Europe, 2015 ~ 22. Diabetes Therapeutic Segment: Growth Opportunities, Europe, 2016–2025~ 23. Diabetes Therapeutic Segment: Insulin Glargine Biosimilars Adoption Rate, Europe, 2014–2025~ 24. Diabetes Therapeutic Segment: Insulin Glargine Biosimilars Patient Population, Europe, 2014 and 2025~ 25. Diabetes Therapeutic Segment: Lantus Price and Biosimilars Discount, Europe, 2014–2025~ 26. Rheumatoid Arthritis Therapeutic Segment: Top-selling Biotech Drugs, Europe, 2015 ~ 27. Rheumatoid Arthritis Therapeutic Segment: Growth Opportunities, Europe, 2016–2025~ 28. Rheumatoid Arthritis Therapeutic Segment: Etanercept Biosimilars Adoption Rate, Europe, 2014–2025~ 29. Rheumatoid Arthritis Therapeutic Segment: Etanercept Biosimilar Patient Population, Europe, 2014 and 2025~ 30. Rheumatoid Arthritis Therapeutic Segment: Enbrel® Price and Biosimilars Discount, Europe, 2014–2025~ 31. Rheumatoid Arthritis Therapeutic Segment: Infliximab Biosimilars Adoption Rate, Europe, 2014–2025~ 32. Rheumatoid Arthritis Therapeutic Segment: Infliximab Biosimilars Patient Population, Europe, 2014 and 2025~ 33. Rheumatoid Arthritis Therapeutic Segment: Remicade® Price and Biosimilars Discount, Europe, 2014–2025~ 34. Rheumatoid Arthritis Therapeutic Segment: Adalimumab Biosimilars Adoption Rate, Europe, 2014–2025~ 35. Rheumatoid Arthritis Therapeutic Segment: Adalimumab Biosimilars Patient Population, Europe, 2014 and 2025~ 36. Total Biosimilars Market: Key M&A Assessment, Europe, 2015–16~ 37. Total Biosimilars Market: Key M&A Assessment, Europe, 2015–16~ 38. Total Biosimilars Market: Key Biosimilars under Review, Europe, 2015–16~ 39. Total Biosimilars Market: Regulatory Approval Pathway in Europe, 2016 ~ 40. Total Biosimilars Market: Impact of Country-level Policies, Europe, 2016~ 41. Total Biosimilars Market: Strategies for Foreign Participants, Europe, 2016~ 42. Total Biosimilars Market: Assessing the Future Impact of Trends, Disruptive Technologies, and New Business Models, Europe, 2016–2025~ 43. Total Biosimilars Market: Comparison of Generics, Biologics, and Biosimilars, Europe, 2016~ 44. Total Biosimilars Market: Key Trends and Highlights, Global, 2015–2016~ 45. Total Biosimilars Market: Differences in the Manufacturing Processes of Biologics and Biosimilars, Global, 2015–2016~ 46. Total Biosimilars Market: Data Requirements for Biosimilar Development, Global, 2016~ 47. Total European Biosimilars Market: Timeline of Key Events, Global, 2015~ 48. Total Biosimilars Market: A Comparison of Market Players, Europe, 2016~ 49. Total Biosimilars Market: List of Biosimilars Approved, Europe, 2016~ 50. Total Biosimilars Market: List of Biosimilars under Review by EMA, Europe, 2016~| 1. Total Biosimilar Market: Percent Revenue Forecast by Region, Global, 2016 and 2025~ 2. Total Biosimilars Market: Revenue Forecast, Global, 2015–2025~ 3. Total Biosimilars Market: Revenue Forecast by Region, Global, 2015–2025~ 4. Total Biosimilars Market: Percent Revenue Forecast by Region, Global, 2015–2025~ 5. Total Biosimilars Market: Impact Mapping of Drivers and Restraints, Europe, 2017–2025~ 6. Total Biosimilars Market: Percent Revenue Forecast by Region, Global, 2015–2025~ 7. Total Biosimilars Market: Revenue Forecast, Europe, 2015–2025~ 8. Total Biosimilars Market: Revenue Forecast by Molecule Type, Europe, 2015–2025~ 9. Oncology Therapeutic Segment: Trastuzumab Patient Population Forecast, Europe, 2015–2025~ 10. Oncology Therapeutic Segment: Trastuzumab Revenue Forecast, Europe, 2015–2025~ 11. Oncology Therapeutic Segment: Bevacizumab Biosimilars Patient Population Forecast, Europe, 2015–2025~ 12. Oncology Therapeutic Segment: Bevacizumab Biosimilars Revenue Forecast, Europe, 2015–2025~ 13. Diabetes Therapeutic Segment: Insulin Glargine Biosimilars Patient Population Forecast, Europe, 2015–2025~ 14. Diabetes Therapeutic Segment: Insulin Glargine Biosimilars Revenue Forecast, Europe, 2015–2025~ 15. Rheumatoid Arthritis Therapeutic Segment: Etanercept Biosimilars Patient Population Forecast, Europe, 2015–2025~ 16. Rheumatoid Arthritis Therapeutic Segment: Etanercept Revenue Forecast, Europe, 2015–2025~ 17. Rheumatoid Arthritis Therapeutic Segment: Infliximab Biosimilars Patient Population Forecast, Europe, 2015–2025~ 18. Rheumatoid Arthritis Therapeutic Segment: Infliximab Revenue Forecast, Europe, 2015–2025~ 19. Rheumatoid Arthritis Therapeutic Segment: Adalimumab Biosimilars Patient Population Forecast, Europe, 2015–2025~ 20. Rheumatoid Arthritis Therapeutic Segment: Adalimumab Revenue Forecast, Europe, 2015–2025~ 21. Total Biosimilars Market: Percent of Sales, Europe, 2015~ 22. Total Biosimilars Market: Regional Growth Rates, Global, 2015~ 23. Total Biosimilars Market: Adoption of Biosimilar Infliximab as a % of the Total Infliximab Market, Scandinavia, 2016~ 24. Total Biosimilars Market: Timeline for the Development of a Biosimilar Medicine, Global, 2015–2016~ |
Lightbox Content | World Cancer Day 2019|Get 15% discount for all Healthcare studies |https://store.frost.com/contacts/?utm_source=PD&utm_medium=lightbox&utm_campaign=HEALTHCARE_CANCER2019 |
Author | Saravanan Thangaraj |
Industries | Healthcare |
WIP Number | MCAA-01-00-00-00 |
Is Prebook | No |